The two companies have been involved in recent licensing deals.
ApexOnco Front Page
Recent articles
The company discontinues the Lag3 project in lung cancer.
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
A son of glembatumumab vedotin has just started its phase 1 study.
The company will start its confirmatory bexobrutideg study in June.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
